INCY Incyte Corporation

117.42
+0.2  (0.17%)
Previous Close 117.22
Open 118.27
Price To book 59.65
Market Cap 22.12B
Shares 188,385,000
Volume 1,752,099
Short Ratio 3.43
Av. Daily Volume 1,405,600

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 planned.
Epacadostat with Keytruda
Squamous cell carcinoma of the head and neck cancer
Phase 3 planned.
Epacadostat with Keytruda
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
Announced January 19 2016 NDA filing by partner Eli Lilly. Noted January 13 2017 that its PDUFA date has been extended three months. Estimate April 14, 2017.
Baricitinib
Rheumatoid arthritis
Phase 2 initiated October 2015
Ruxolitinib cream
Topical treatment of alopecia areata
Phase 2 ongoing
Ruxolitinib
Non-small cell lung cancer (NSCLC)
Approved December 4 2014
Jakafi (ruxolitinib) (RESPONSE)
Polycythemia Vera
Phase 3 initiated June 2016. Initial data due 2018
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Phase 1/2 in combination with osimertinib (EGFR) expected to initiate 4Q 2016.
INCB39110 with osimertinib (EGFR)
Lung cancer
Ongoing
Epacadostat
Cancer - multiple tumor types
Endpoint not met, mid-2014
Jakafi (ruxolitinib) (RELIEF)
Disease-related symptoms in patients with Polycythemia Vera
Phase 2 trial stopped January 2016 due to lack of efficacy
Ruxolitinib
Colorectal cancer
Phase 3 trial discontinued due to lack of efficacy
Ruxolitinib - JANUS 1 and JANUS 2
Cancer - Pancreatic
Phase 3 to be initiated 4Q 2016.
Ruxolitinib
Graft versus host disease

Latest News

  1. Incyte Has Insight Into Market With Potential Blockbuster Drugs
  2. INCYTE CORP Files SEC form 8-K, Other Events
  3. Merus Announces Closing of Global Strategic Research Collaboration with Incyte to Discover and Develop Bispecific Antibodies
  4. Merus Announces Closing of Global Strategic Research Collaboration with Incyte to Discover and Develop Bispecific Antibodies
  5. We’re in the year of the biotech buyout, and here are five prime targets
  6. Coverage initiated on Incyte by Credit Suisse
  7. Gilead, Merck, Alexion 2017 Views Hazy; Biogen May Surge: Analyst
  8. Leading Stocks That Are Driving A Hot Mutual Fund's Rally
  9. Is LLY's Arthritis Drug Delay a Minor Setback?
  10. Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse
  11. Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended
  12. U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment
  13. Merck Carries Incyte On Keytruda Coattails In 4 'Hot' Tumors: Leerink
  14. Small Caps Soar, Dow Off; Which Tech Stocks Beat Apple In Gains Today?
  15. Incyte's Prospects Get Even Brighter With Merck Announcement
  16. Incyte/Merck to Start More Epacadostat-Keytruda Studies
  17. Jefferies Has 5 Top Biotech Stocks to Buy for 2017
  18. Incyte Stock Breaks Out, It And Partner Merck Will Advance Key Trial
  19. Biotech, Chip Stocks Lift Nasdaq To Fresh Closing High
  20. Nasdaq hits all-time high

SEC Filings

  1. 8-K - Current report 17541135
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals
  3. 8-K - Current report 162064011
  4. 8-K - Current report 162056484
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 162045547
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 161964899
  7. 8-K - Current report 161963244
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 161818966
  9. 8-K - Current report 161816026
  10. 8-K - Current report 161773573